DiviTum® is an innovative biomarker assay developed with the aim to monitor and predict treatment response in cancer therapy. The test measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. In normal cells, TK activity is hardly detectable, but in proliferating cells, its levels increase. Since the degree of TK activity is highly associated with the rate of cell proliferation, it is a particularly suitable biomarker for measuring tumor aggressiveness. Moreover, it offers several advantages over alternative techniques, e.g. rapid evaluation of response and avoids invasive testing. Biovica is currently engaged in several clinical studies designed to generate high-impact, high-quality clinical data on the performance of DiviTum® with a number of different solid tumor types and cell-cycle regulating drugs.